Showing results (651-660 of 692) with videos related to

Sort By:
Pageof 70
Nature Medicine|November 4, 2024
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitisHanna Pulaski, Stephen A Harrison, Shraddha S Mehta, et al.
Journal of Hepatology|July 25, 2026
A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn BiomarkersMorten A Karsdal, Anne-Christine Bay-Jensen, Daniel Guldager Kring Rasmussen, et al.
JCI Insight|November 22, 2019
Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosisJasmohan S Bajaj, Nita Salzman, Chathur Acharya, et al.
Nature Medicine|August 7, 2024
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseasesJanani S Iyer, Dinkar Juyal, Quang Le, et al.
Hepatology Communications|November 22, 2017
Role of Aramchol in steatohepatitis and fibrosis in miceMarta Iruarrizaga-Lejarreta, Marta Varela-Rey, David Fernández-Ramos, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 8, 2025
Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-associated SteatohepatitisArun J Sanyal, Atsushi Nakajima, Elisabetta Bugianesi, et al.
JAMA|August 22, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical TrialChristoph D Spinner, Robert L Gottlieb, Gerard J Criner, et al.
Journal of Clinical and Experimental Hepatology|February 12, 2026
Type 2 Diabetes Mellitus and Risk of Advanced Fibrosis in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Results of Multi-centre Indian Consortium on MASLD (ICOM-D) StudyNarendra S Choudhary, Ajay Duseja, Arka De, et al.
Nature Reviews. Gastroenterology & Hepatology|June 7, 2024
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus StatementBrian P Lee, Katie Witkiewitz, Jessica Mellinger, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
Pageof 70